• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

印度一名接受注射用巴龙霉素治疗内脏利什曼病的患者出现了黑热病后皮肤利什曼病。

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.

机构信息

Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Agamkuan, Patna, Bihar, India.

出版信息

J Clin Microbiol. 2012 Apr;50(4):1478-9. doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.

DOI:10.1128/JCM.05966-11
PMID:22278840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3318524/
Abstract

Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation that usually develops after treatment of visceral leishmaniasis (VL), a major public health problem in India. The diagnosis and management of PKDL is complex. This is the first case report from India in which PKDL occurred after paromomycin treatment for VL in an Indian patient.

摘要

晚期皮肤利什曼病（PKDL）是内脏利什曼病（VL）治疗后常出现的皮肤表现，VL 在印度是一个主要的公共卫生问题。PKDL 的诊断和治疗较为复杂。本文报告了首例印度患者经巴龙霉素治疗 VL 后发生 PKDL 的病例。

相似文献

1
Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.印度一名接受注射用巴龙霉素治疗内脏利什曼病的患者出现了黑热病后皮肤利什曼病。
J Clin Microbiol. 2012 Apr;50(4):1478-9. doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.
2
Advanced case of PKDL due to delayed treatment: A rare case report.由于延迟治疗导致的晚期皮肤利什曼病：一例罕见病例报告。
PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008052. doi: 10.1371/journal.pntd.0008052. eCollection 2020 Mar.
3
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.利用重点药物警戒确保孟加拉国国家黑热病消除规划中抗利什曼原虫药物的患者安全。
Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.
4
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.印度比哈尔邦内脏利什曼病流行地区的黑热病后皮肤利什曼病。
Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.
5
Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.在印度比哈尔邦，采用20毫克/千克脂质体两性霉素B（安必素）治疗原发性内脏利什曼病后出现的黑热病后皮肤利什曼病。
PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2611. doi: 10.1371/journal.pntd.0002611. eCollection 2014.
6
Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.两性霉素B脂质体治疗内脏利什曼病后发生的黑热病后皮肤利什曼病：对印度消除计划的一个潜在挑战
J Postgrad Med. 2013 Jul-Sep;59(3):226-8. doi: 10.4103/0022-3859.118046.
7
Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.内脏利什曼病和卡拉·阿扎尔后皮肤利什曼病分离株的体外药物敏感性模式存在显著差异。
Parasitol Res. 2013 Mar;112(3):1001-9. doi: 10.1007/s00436-012-3222-1. Epub 2012 Dec 18.
8
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.米替福新治疗内脏利什曼病和黑热病后皮肤利什曼病病例中利什曼原虫分离株的药物敏感性。
PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.
9
An unusual paediatric case of post-kala-azar dermal leishmaniasis: a hidden parasite under the veil of white.一例罕见的黑热病后皮肤利什曼病儿科病例：白色面纱下隐藏的寄生虫。
Clin Microbiol Infect. 2023 Jun;29(6):803-804. doi: 10.1016/j.cmi.2023.03.004. Epub 2023 Mar 12.
10
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.印度比哈尔邦三种不同内脏利什曼病治疗方案后复发和黑热病后皮肤利什曼病的长期发病率。
PLoS Negl Trop Dis. 2020 Jul 20;14(7):e0008429. doi: 10.1371/journal.pntd.0008429. eCollection 2020 Jul.

引用本文的文献

1
Combination Therapy for Post-Kala-Azar Dermal Leishmaniasis: A Literature Review of Current Evidence.黑热病后皮肤利什曼病的联合治疗：当前证据的文献综述
Indian J Dermatol. 2024 Sep-Oct;69(5):396-405. doi: 10.4103/ijd.ijd_612_22. Epub 2024 Oct 29.
2
Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.印度次大陆的无黑热病皮肤利什曼病：消除的挑战与策略。
Front Immunol. 2023 Aug 11;14:1236952. doi: 10.3389/fimmu.2023.1236952. eCollection 2023.
3
Leishmaniasis: where are we and where are we heading?利什曼病：我们在哪里，我们要往哪里去？
Parasitol Res. 2021 May;120(5):1541-1554. doi: 10.1007/s00436-021-07139-2. Epub 2021 Apr 7.
4
Mixed Cutaneous Infection Caused by Leishmania and Dermatophytes: A Rare Coincidence or Immunological Fact.利什曼原虫和皮肤癣菌引起的混合皮肤感染：罕见巧合还是免疫事实？
Case Rep Dermatol Med. 2021 Mar 8;2021:5526435. doi: 10.1155/2021/5526435. eCollection 2021.
5
A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.一项评价脂质体两性霉素 B（AmBisome）与米替福新治疗内脏利什曼病后皮肤利什曼病的随机、开放性研究，评估其疗效和安全性。
Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):34-41. doi: 10.25259/IJDVL_410_19.
6
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.印度比哈尔邦三种不同内脏利什曼病治疗方案后复发和黑热病后皮肤利什曼病的长期发病率。
PLoS Negl Trop Dis. 2020 Jul 20;14(7):e0008429. doi: 10.1371/journal.pntd.0008429. eCollection 2020 Jul.
7
Post kala-azar dermal leishmaniasis: A threat to elimination program.无鞭毛体利什曼原虫病皮肤后：消除规划的威胁。
PLoS Negl Trop Dis. 2020 Jul 2;14(7):e0008221. doi: 10.1371/journal.pntd.0008221. eCollection 2020 Jul.
8
Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy.脂质体两性霉素 B（Fungisome）联合短程米替福新与米替福新单药治疗印度内脏利什曼病的疗效比较。
Am J Trop Med Hyg. 2020 Jul;103(1):308-314. doi: 10.4269/ajtmh.19-0931. Epub 2020 May 7.
9
Advanced case of PKDL due to delayed treatment: A rare case report.由于延迟治疗导致的晚期皮肤利什曼病：一例罕见病例报告。
PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008052. doi: 10.1371/journal.pntd.0008052. eCollection 2020 Mar.
10
Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.内脏利什曼病治疗方案与黑热病后皮肤利什曼病和内脏利什曼病复发的关系：来自孟加拉国的队列研究。
PLoS Negl Trop Dis. 2019 Aug 15;13(8):e0007653. doi: 10.1371/journal.pntd.0007653. eCollection 2019 Aug.

本文引用的文献

1
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs.印度、尼泊尔和孟加拉国流行地区内脏利什曼病主动病例检测的选择，比较其检出率、可行性和成本。
PLoS Negl Trop Dis. 2011 Feb 8;5(2):e960. doi: 10.1371/journal.pntd.0000960.
2
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.简短报告：米替福新治疗内脏利什曼病后出现的黑热病后皮肤利什曼病（PKDL）
Am J Trop Med Hyg. 2009 Mar;80(3):336-8.
3
Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.苏丹的利什曼病。黑热病后皮肤利什曼病。
Trans R Soc Trop Med Hyg. 2001 Apr;95 Suppl 1:S59-76. doi: 10.1016/s0035-9203(01)90219-6.
4
Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis.开发一种用于检测黑热病和黑热病后皮肤利什曼病患者临床样本中杜氏利什曼原虫的种特异性聚合酶链反应检测方法。
J Clin Microbiol. 2001 Mar;39(3):849-54. doi: 10.1128/JCM.39.3.849-854.2001.
5
Treatment of post-kala-azar dermal leishmaniasis.黑热病后皮肤利什曼病的治疗。
Int J Dermatol. 1995 Sep;34(9):668-9. doi: 10.1111/j.1365-4362.1995.tb01112.x.